CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.
- Mechanism
- Curator reviewed
CRx-139 inhibits certain pro-inflammatory biomarkers, such as TNF-alpha, IL-6 and CRP and increases the anti-inflammatory cytokine IL-10.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- CRx-139
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CRx-139, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account